UCB Reports Interim Results of Bimekizumab in P-III BE OPTIMAL Study for the Treatment of Active Psoriatic Arthritis
Shots:
- The P-III BE OPTIMAL study evaluates bimekizumab vs PBO in 852 patients with active PsA who are biologic disease-modifying anti-rheumatic drug naïve
- The trial met its 1EPs & 2EPs i.e., patients treated with bimekizumab achieved an improvement in signs & symptoms of the disease from baseline as measured by ACR 50 response (50% vs 20%) @16wks., improvements in physical function as measured by HAQ-DI; skin clearance as measured by 90% improvement in PASI 90; joint radiographic progression as measured by vdHmTSS @16wks.
- The safety profile was consistent with previous studies & no new safety signals were observed. The therapy is currently under US FDA’s review to treat PsO
Ref: PRNewswire | Image: UCB
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com